Prevalence of Molecular Diagnoses for Usher Syndrome and the Need for Coordinated Care
The Laryngoscope · 2025
DOI: 10.1002/lary.31911 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Laryngoscope, 2025. Verfasst von Brett M Colbert und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology, University of Miami Miller School of Medicine, Miami, Florida, U.S.A. Hauptthemen laut MEDLINE: Usher Syndromes, Genetic Testing, Molecular Diagnostic Techniques. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIDCD NIH HHS, Research to Prevent Blindness-Unrestricted Grant, NEI NIH HHS.
Abstract (Originalsprache)
Introduction
Usher syndrome (USH) is a rare, autosomal‐recessive genetic disorder and a leading cause of early onset deaf‐blindness. A clinical diagnosis is made by the presence of retinitis pigmentosa (RP) with sensorineural hearing loss (SNHL). Subtype (USH1, USH2, USH3) is determined by severity and age of onset. Molecular testing is able to further distinguish USH subtypes by causative gene. As gene therapy strategies continue to be explored for USH, it is important to know the underlying genetic cause and to coordinate care among an interdisciplinary team.
Methods
We reviewed charts of 198 individuals presenting to the RP clinic at Bascom Palmer Eye Institute (BPEI) for suspected USH. Demographic information, USH clinical diagnosis, molecular testing, molecular diagnosis, and audiological data were collected.
Results
Of the 198 patients reviewed, 190 (96%) met clinical criteria for USH and received a clinical diagnosis. There were 67 (35%) that had a genetic test with a pathogenic molecular diagnosis. The average ages at molecular diagnosis were USH1B, 20 years old; USH2A, 37 years old; USH2C, 50 years old. Of the 67 with a molecular diagnosis, 23 (34%) established ophthalmic care and 8 of these (11%) established audiological care. Discussion/Conclusion Molecular testing and diagnosis should be part of the routine care of USH individuals to facilitate earlier interventions and coordinated care between ophthalmology and audiology. Level of Evidence 4 Laryngoscope , 135:1777–1780, 2025
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Otolaryngology, University of Miami Miller School of Medicine, Miami, Florida, U.S.A.
- Medical Scientist Training Program, University of Miami Miller School of Medicine, Miami, Florida, U.S.A.
- Dr. John T. Macdonald Foundation Department of Human Genetics, John P. Hussman Institute for Human Genomics, University of Miami Miller School of Medicine, Miami, Florida, U.S.A.
- Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida, U.S.A.
- Department of Biochemistry, University of Miami Miller School of Medicine, Miami, Florida, U.S.A.
ORCID-Profile: Xue Z Liu
Förderung
- NIDCD NIH HHS
- Research to Prevent Blindness-Unrestricted Grant
- NEI NIH HHS
- National Eye Institute
- National Institute on Deafness and Other Communication Disorders
Zitieren
APA
Colbert, B. M., Smeal, M., Cromar, Z. J., Rosa, P., Blanton, S. H., Lam, B. L., & Liu, X. Z. (2025). Prevalence of Molecular Diagnoses for Usher Syndrome and the Need for Coordinated Care. The Laryngoscope. https://doi.org/10.1002/lary.31911
Vancouver
Colbert BM, Smeal M, Cromar ZJ, Rosa P, Blanton SH, Lam BL, et al. Prevalence of Molecular Diagnoses for Usher Syndrome and the Need for Coordinated Care. The Laryngoscope. 2025. doi:10.1002/lary.31911
BibTeX
@article{Colbert2025,
author = {Colbert, Brett M and Smeal, Molly and Cromar, Zachary J and Rosa, Potyra and Blanton, Susan H and Lam, Byron L and Liu, Xue Z},
title = {Prevalence of Molecular Diagnoses for Usher Syndrome and the Need for Coordinated Care},
journal = {The Laryngoscope},
year = {2025},
doi = {10.1002/lary.31911}
}
EUVIMED